LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES
LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES
لف الصورة للتكبير في انقر على الصورة للتكبير
LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES
LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES
LZCap™ AG(3'Acm) is a Cap1 analog, can be used as the capping agent for producing mRNAs in an "one-pot"process. Under the action of T7 polymerase, mRNA with 5' end Cap 1 structure was generated by cotranscription using LZCap™ AG(3'Acm), NTPs, and template DNA. The capped mRNA could be directly translated and expressed in cells and in vivo. It is widely used in the fields of in vitro transcription, gene editing, vaccine development, tumor CAR-T therapy, protein substitution therapy and regenerative medicine.LZCap™ AG(3'Acm) requires the T7 promoter with AG as the starting...

Frequently Bought Together

LZCap™ AG (3'Acm) GMP-Grade, High Affinity (100 mM) _ 10684ES

YeasenSKU: 10684ES60
Size: 100 μL
سعر:
$695.00
مخزون:
في الأوراق المالية

LZCap™ AG(3'Acm) is a Cap1 analog, can be used as the capping agent for producing mRNAs in an "one-pot"process. Under the action of T7 polymerase, mRNA with 5' end Cap 1 structure was generated by cotranscription using LZCap™ AG(3'Acm), NTPs, and template DNA. The capped mRNA could be directly translated and expressed in cells and in vivo. It is widely used in the fields of in vitro transcription, gene editing, vaccine development, tumor CAR-T therapy, protein substitution therapy and regenerative medicine.
LZCap™ AG(3'Acm) requires the T7 promoter with AG as the starting sequence. LZCap™ AG(3'Acm) can provide>97%capped mRNA, and up to 100-200 μg capped mRNA can be generated with 1 μg DNA template per standard reaction

Specifications

Cat.No.

10684ES60/10684ES80

Size

100 μL/1 mL

Molecular Formula

C35H48N16O24P4（Free acid）

Molecular Weight

1200.75（Free acid）

Concentration

100 mM

Purity

HPLC ≥90%

Salt type

NH4+

Structure

Components

Name

10684ES60

10684ES80

LZCap™ AG(3'Acm) GMP-grade (100 mM)

100 μL

1 mL

Figures

1. High Yield and Capping Efficiency of LZCap

With LZCap AG(3'Acm) cap, the luciferase mRNA capping efficiency is about 97.59%, and up to 200 μg capped mRNA can be obtained with 1 μg DNA template in a standard in vitro transcription (IVT) reaction with T7 RNA polymerase. The mRNA purity is up to 99% after simple LiCl precipitation. This high capping efficiency and yield make LZCap an attractive option for various applications, including protein production and gene therapy.

Product

Cap AG (3'-OMe-7mG)

LZCap AG(3'Acm)

AG (no capping)

mRNA yield (μg)

164

173

200

Figure 1. MS analysis of the capping efficiency of LZCapped Luciferase mRNA with RNAse H based method. The capping efficiency is about 97.59%.

Figure 1. MS analysis of the capping efficiency of LZCapped Luciferase mRNA with RNAse H based method. The capping efficiency is about 97.59%.

Storage

This product should be stored at -25~-15℃ for 2 years

FAQ

mRNAs with LZCap AG(3'Acm) and LZCap AG M6 (3'Acm) show higher resistance towards the decapping enzyme (NEB). It is noted that CapM6 (3'-OMe-6mA-7mG) is also resistant to decapping enzym, but the regular Cap AG (3'-OMe-7mG) does not show the resistance. Due to the high affinity of LZCap, the low input of cap1 analog shows perfect performance when used alongside our Hieff™ T7 RNA polymerase (Cat: 10628).
The expression of LZCap AG(3'Acm) capped luciferase mRNA is significantly higher than that of the Cap1 analog (3'-OMe-7mG) capped mRNA in different cell lines* (3T3-L1，Hela，JAWs， HEK293T and Huh7)，The 130 repetition experiment showed about a 1.5 times higher expression of LZCap AG(3'Acm) capped luciferase mRNA than the (3'-OMe-7mG) capped mRNA on average. Similar result is observed in mice. Protein expression level may vary slightly with different mRNA sequence.
The expression efficiency of LZCap AG(3'Acm) or LZCap AG(3'FMom) capped GLuc encoding mRNA shows a higher in vivo expression relative to CapAG (3'-OMe-7mG) capped mRNAs in Cynomolgus Monkey and Pig.
LZCapAG ( 3'Acm ) capped mRNAs show low innate immunogenicity. TLR8, TLR7, IL-1A and B play an important role in the immune response induced by uncapped RNA. The in vivo studies of LZCapped mRNA immunogenicity analysis showed that uncapped RNA caused significant changes in the transcription level of immune-related factors in mice. Both LZCap and 3'-OMe-7mG capped mRNAs display similar lower immune factor transcription level in mice after a single RNA-stimulated injection.
Yes, we did Cytotoxicity Test, Human Polymerase Inhibition Study and Ames Test. There are no or little cytotoxicity observed for the nucleoside monomer of 3'-Acm-7mG（CC50＞10000nM）in 293T、Huh7、MRC5、THP1 and U87MG cells. Human DNA polymerase ( α ,β , γ and Klenow) and mitochondrial RNA polymerase (hPOLRMT) activity inhibition studies show that 3'-Acm-7mG TP does not inhibit human DNA or RNA polymerase. The bacterial reverse mutation test (Ames) detects associated genetic alterations, as well as genotoxic carcinogens in most rodents and humans. Ames test showed 3'-Acm-7mG has no genotoxicity.
Yes. The patent has been granted in the USA.

Citations

Documents

Applications

You may also like

Inquiry

FAQ

The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.

Certain applications may require additional third-party intellectual property rights.

Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.